Literature DB >> 20235887

Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).

David J Kwiatkowski1.   

Abstract

Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC) are highly desired to enable detailed investigation of the pathogenesis of these diseases. Multiple rats and mice have been generated in which a mutation similar to that occurring in TSC patients is present in an allele of Tsc1 or Tsc2. Unfortunately, these mice do not develop pathologic lesions that match those seen in LAM or TSC. However, these Tsc rodent models have been useful in confirming the two-hit model of tumor development in TSC, and in providing systems in which therapeutic trials (e.g., rapamycin) can be performed. In addition, conditional alleles of both Tsc1 and Tsc2 have provided the opportunity to target loss of these genes to specific tissues and organs, to probe the in vivo function of these genes, and attempt to generate better models. Efforts to generate an authentic LAM model are impeded by a lack of understanding of the cell of origin of this process. However, ongoing studies provide hope that such a model will be generated in the coming years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20235887      PMCID: PMC2883495          DOI: 10.1089/lrb.2009.0013

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  39 in total

1.  Protective effect of pregnancy for development of uterine leiomyoma.

Authors:  C L Walker; K Cesen-Cummings; C Houle; D Baird; J C Barrett; B Davis
Journal:  Carcinogenesis       Date:  2001-12       Impact factor: 4.944

2.  Genetic identification of a locus, Mot1, that affects renal tumor size in the rat.

Authors:  R S Yeung; H Gu; M Lee; T A Dundon
Journal:  Genomics       Date:  2001-12       Impact factor: 5.736

3.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

Authors:  Heidi L Kenerson; Lauri D Aicher; Lawrence D True; Raymond S Yeung
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

4.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

Authors:  David J Kwiatkowski; Hongbing Zhang; Jennifer L Bandura; Kristina M Heiberger; Michael Glogauer; Nisreen el-Hashemite; Hiroaki Onda
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

5.  A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles.

Authors:  Kristen Pollizzi; Izabela Malinowska-Kolodziej; Cheryl Doughty; Charles Betz; Jian Ma; June Goto; David J Kwiatkowski
Journal:  Hum Mol Genet       Date:  2009-04-08       Impact factor: 6.150

6.  Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.

Authors:  Nisreen El-Hashemite; Victoria Walker; Hongbing Zhang; David J Kwiatkowski
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.

Authors:  Matt Yu Liu; Lorenz Poellinger; Cheryl L Walker
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

9.  Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients.

Authors:  Sandra L Dabora; Penelope Roberts; Andres Nieto; Ron Perez; Sergiusz Jozwiak; David Franz; John Bissler; Elizabeth A Thiele; Katherine Sims; David J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2002-08-21       Impact factor: 11.025

10.  Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.

Authors:  Kristen Pollizzi; Izabela Malinowska-Kolodziej; Michael Stumm; Heidi Lane; David Kwiatkowski
Journal:  Mol Cancer       Date:  2009-06-15       Impact factor: 27.401

View more
  25 in total

Review 1.  The new era of the lymphatic system: no longer secondary to the blood vascular system.

Authors:  Inho Choi; Sunju Lee; Young-Kwon Hong
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

2.  Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Authors:  Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05       Impact factor: 6.914

Review 3.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

4.  Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Authors:  Lisa M Julian; Sean P Delaney; Ying Wang; Alexander A Goldberg; Carole Doré; Julien Yockell-Lelièvre; Roger Y Tam; Krinio Giannikou; Fiona McMurray; Molly S Shoichet; Mary-Ellen Harper; Elizabeth P Henske; David J Kwiatkowski; Thomas N Darling; Joel Moss; Arnold S Kristof; William L Stanford
Journal:  Cancer Res       Date:  2017-08-22       Impact factor: 12.701

5.  Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.

Authors:  Chenggang Li; Na Li; Xiaolei Liu; Erik Y Zhang; Yang Sun; Kouhei Masuda; Jing Li; Julia Sun; Tasha Morrison; Xiangke Li; Yuanguang Chen; Jiang Wang; Nagla A Karim; Yi Zhang; John Blenis; Mauricio J Reginato; Elizabeth P Henske; Jane J Yu
Journal:  JCI Insight       Date:  2016-11-17

6.  Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.

Authors:  Hen Prizant; Aritro Sen; Allison Light; Sung-Nam Cho; Francesco J DeMayo; John P Lydon; Stephen R Hammes
Journal:  Mol Endocrinol       Date:  2013-07-02

7.  Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.

Authors:  Siying Ren; Yongfeng Luo; Hui Chen; David Warburton; Hilaire C Lam; Larry L Wang; Ping Chen; Elizabeth P Henske; Wei Shi
Journal:  Am J Pathol       Date:  2016-10-18       Impact factor: 4.307

8.  A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas.

Authors:  Jarrett D Leech; Stephen H T Lammers; Sam Goldman; Neil Auricchio; Roderick T Bronson; David J Kwiatkowski; Mustafa Sahin
Journal:  Mol Cancer Res       Date:  2014-12-29       Impact factor: 5.852

9.  Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

10.  Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.

Authors:  Victoria Stepanova; Konstantin V Dergilev; Kelci R Holman; Yelena V Parfyonova; Zoya I Tsokolaeva; Mimi Teter; Elena N Atochina-Vasserman; Alla Volgina; Sergei V Zaitsev; Shane P Lewis; Fedor G Zabozlaev; Kseniya Obraztsova; Vera P Krymskaya; Douglas B Cines
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.